Abliva Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
2ndary - Private
- Latest Deal Amount
-
$8.23M
Abliva General Information
Description
Developer of mitochondrial pharmaceutical medicines intended for primary mitochondrial diseases and orphan indications of high unmet medical need. The company incorporates small molecule compounds targeting cellular energy metabolism, with features including oral administration, modulation of NAD+ levels, and multi-organ impact assessment through fatigue and muscle function endpoints, enabling the rare disease market to access targeted therapeutic options with measurable physiological outcomes.
Contact Information
Website
www.abliva.com(Operating Subsidiary)
Corporate Office
- Scheeletorget 1
- 223 81 Lund
- Sweden
Corporate Office
- Scheeletorget 1
- 223 81 Lund
- Sweden
Abliva Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Secondary Transaction - Private | 18-Jun-2025 | $8.23M | Completed | Generating Revenue | ||
| 9. Merger/Acquisition | 14-Feb-2025 | Completed | Generating Revenue | |||
| 8. PIPE | 13-Jun-2022 | Completed | Generating Revenue | |||
| 7. PIPE | 22-Apr-2020 | Completed | Generating Revenue | |||
| 6. PIPE | 07-May-2015 | Completed | Generating Revenue | |||
| 5. PIPE | 11-Feb-2015 | Completed | Generating Revenue | |||
| 4. PIPE | 18-Dec-2013 | Completed | Generating Revenue | |||
| 3. 2PO | 10-Apr-2013 | Completed | Generating Revenue | |||
| 2. IPO | 03-Oct-2008 | $1.5M | $1.5M | Completed | Generating Revenue | |
| 1. Later Stage VC | Completed | Generating Revenue |
Abliva Comparisons
Industry
Financing
Details
Abliva Competitors (38)
One of Abliva’s 38 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Mighty Therapeutics | Private Equity-Backed | Needham, MA | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY |
Abliva Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abliva Patents
Abliva Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025040685-A1 | Quinones for use in the treatment of red blood cell enzymopathies | Inactive | 21-Aug-2023 | ||
| WO-2025040686-A1 | Quinones for use in the treatment of red blood cell enzymopathies | Inactive | 21-Aug-2023 | ||
| AU-2022277623-A1 | Kl1333 for use in medicine | Active | 19-May-2021 | ||
| AU-2022277623-B2 | Kl1333 for use in medicine | Active | 19-May-2021 | ||
| AU-2022277623-B9 | Kl1333 for use in medicine | Active | 19-May-2021 | A61K31/4184 |
Abliva Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abliva Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andra AP-fonden | Asset Manager | Minority | ||
| Hadean Ventures | Venture Capital | Minority | ||
| IP Group | Venture Capital | Minority | ||
| LU Ventures (Lund) | Corporate Venture Capital | Minority | ||
| Rhenman Healthcare Equity | Hedge Fund | Minority |
Abliva Investments & Acquisitions (2)
Abliva’s most recent deal was a Secondary Transaction - Private with Isomerase for . The deal was made on 15-Aug-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Isomerase | 15-Aug-2016 | Secondary Transaction - Private | Biotechnology | ||
| Biotica Technology | 11-Mar-2013 | Merger/Acquisition | Biotechnology |
Abliva ESG
Risk Overview
Risk Rating
Updated February, 29, 2024
29.22 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Biotechnology
Subindustry
of 444
Rank
Percentile
Abliva FAQs
-
When was Abliva founded?
Abliva was founded in 2000.
-
Where is Abliva headquartered?
Abliva is headquartered in Lund, Sweden.
-
What is the size of Abliva?
Abliva has 1 total employees.
-
What industry is Abliva in?
Abliva’s primary industry is Drug Discovery.
-
Is Abliva a private or public company?
Abliva is a Private company.
-
What is the current valuation of Abliva?
The current valuation of Abliva is .
-
What is Abliva’s current revenue?
The current revenue for Abliva is .
-
How much funding has Abliva raised over time?
Abliva has raised $27.1M.
-
Who are Abliva’s investors?
Andra AP-fonden, Hadean Ventures, IP Group, LU Ventures (Lund), and Rhenman Healthcare Equity have invested in Abliva.
-
Who are Abliva’s competitors?
AnTolRx, Mighty Therapeutics, Vedanta Biosciences, Xenetic Biosciences, and Cognition Therapeutics are some of the 38 competitors of Abliva.
-
When was Abliva acquired?
Abliva was acquired on 18-Jun-2025.
-
Who acquired Abliva?
Abliva was acquired by Pharming Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
